Differences Between Suicide Attempters and Suicide Ideators. Influence of the Brief Therapy Attempted Suicide Short Intervention Program (ASSIP) on Neuropsychological Correlates and Psychological Process Factors - Project 2
Launched by UNIVERSITY OF BERN · Feb 8, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the mental health patterns of people who have thought about suicide compared to those who have actually attempted it. The main focus is to see how a specific treatment called the Attempted Suicide Short Intervention Program (ASSIP) can help improve these patterns. Participants who have previously attempted suicide will be randomly assigned to either receive the ASSIP therapy or standard care, which includes a resource interview. The study will take place at the University Hospital of Psychiatry and Psychotherapy in Bern, Switzerland.
To be eligible for this study, individuals must be at least 18 years old, have a history of at least one suicide attempt, and be willing to participate in the ASSIP therapy. They should also own a smartphone. Participants will be assessed at the start of the study and then again 4 weeks and 12 months later to see how they are doing. It's important to note that individuals with serious cognitive impairments or certain mental health disorders may not be included in the study. This trial aims to understand better how different treatments can support those struggling with suicidal thoughts and behaviors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria for Project 2:
- Subjects fulfilling the following inclusion criteria are eligible for the study:
- • Informed consent as documented by signature
- • Age ≥ 18 years
- • At least one previous suicide attempt
- • Willingness to attend the ASSIP brief therapy
- • Owns a smartphone
- Exclusion Criteria for Project 2:
- The presence of any one of the following exclusion criteria will lead to exclusion of the subject:
- • Serious cognitive impairment
- • Any psychotic disorder
- • Any current medication, which substantially impairs the attention span, reaction, rate or any other relevant cognitive functions
- • Inability to follow the procedures of the study (e.g., insufficient mastery of the German language, previous enrolment into the current study)
About University Of Bern
The University of Bern, a leading research institution in Switzerland, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, the university fosters an environment where scientific inquiry and clinical application intersect. Its commitment to ethical standards and patient safety ensures that all trials are conducted with the highest integrity, striving to contribute valuable insights to the global medical community. The University of Bern actively engages in diverse therapeutic areas, aiming to translate research findings into tangible health solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Anja C. Gysin-Maillart, PhD
Principal Investigator
University of Bern, University Hospital of Psychiatry, Translational Research Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported